{"nctId":"NCT00627445","briefTitle":"Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2008-02"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":441,"armGroups":[{"label":"BIAsp 50-50-30","type":"EXPERIMENTAL","interventionNames":["Drug: biphasic insulin aspart 30","Drug: metformin","Drug: biphasic insulin aspart 50"]},{"label":"BIAsp 30-30","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: biphasic insulin aspart 30","Drug: metformin"]}],"interventions":[{"name":"biphasic insulin aspart 30","otherNames":[]},{"name":"metformin","otherNames":[]},{"name":"biphasic insulin aspart 50","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes\n* Currently treated with premix human insulin twice daily with or without oral antidiabetic drugs for at least 3 months\n* HbA1c (Glycosylated Haemoglobin A1c) between 7.5% - 12.0% (both inclusive)\n* FPG (Fasting Plasma Glucose) higher than 7.0 mmol/L\n* BMI (Body Mass Index) 23-40 kg/sq.m (both inclusive)\n\nExclusion Criteria:\n\n* Metformin contraindications according to local practice\n* Systemic use of TZDs (thiazolidinediones) for more than 1 month within 6 months prior to this trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Haemoglobin A1c (HbA1c)","description":"Change in glycosylated haemoglobin A1c (HbA1c) from week 0 (baseline) to end of treatment (week 16)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.790","spread":"0.057"},{"groupId":"OG001","value":"-1.517","spread":"0.056"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Subjects Achieving HbA1c Treatment Targets","description":"The percentage of subjects who after 16 weeks of treatment met the glycosylated haemoglobin A1c (HbA1c) treatment targets below 7%, or below or equal to 6.5%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Change and Daily Average in 8-point Plasma Glucose","description":"Change in 8-point plasma glucose from baseline (week 0) to at end of treatment (week 16). 8-point plasma glucose was measured at following time points: Before each meal, 120 minutes after the start of each meal, at bedtime, and at 3:00 AM in the morning. Daily average was calculated at the end of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.52","spread":"0.10"},{"groupId":"OG001","value":"-2.43","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.92","spread":"0.17"},{"groupId":"OG001","value":"-4.00","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.80","spread":"0.13"},{"groupId":"OG001","value":"-2.71","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.37","spread":"0.19"},{"groupId":"OG001","value":"-3.15","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.83","spread":"0.16"},{"groupId":"OG001","value":"-2.83","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.46","spread":"0.18"},{"groupId":"OG001","value":"-3.37","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.93","spread":"0.15"},{"groupId":"OG001","value":"-3.09","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.99","spread":"0.13"},{"groupId":"OG001","value":"-1.89","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.23","spread":"0.10"},{"groupId":"OG001","value":"-2.94","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change and Daily Average in Prandial Plasma Glucose Increment","description":"Change in prandial (mealtime) plasma glucose increment from baseline (week 0) to end of treatment (week 16). Daily average prandial plasma glucose increment was calculated at end of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.41","spread":"0.16"},{"groupId":"OG001","value":"-1.58","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.57","spread":"0.19"},{"groupId":"OG001","value":"-0.44","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.18"},{"groupId":"OG001","value":"-0.53","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"0.11"},{"groupId":"OG001","value":"-0.84","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"The Total Increase in Total Daily Insulin Dose Per Body Weight","description":"The total increase in total daily insulin dose per body weight from baseline (week 0) to end of treatment (week 16).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.963","spread":"0.016"},{"groupId":"OG001","value":"0.820","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change in body weight from baseline (week 0) to end of treatment (week 16)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.188","spread":"0.157"},{"groupId":"OG001","value":"0.817","spread":"0.155"}]}]}]},{"type":"SECONDARY","title":"Number of Hypoglycaemic Episodes","description":"Number of hypoglycaemic episodes occurring after baseline (week 0) to the end of treatment (week 16) in each treatment group. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. Symptoms only if subject was able to treat her/himself and with either no plasma glucose or blood glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L or 56 mg/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"728","spread":null},{"groupId":"OG001","value":"679","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"570","spread":null},{"groupId":"OG001","value":"481","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Nocturnal Hypoglycaemic Episodes","description":"Number of nocturnal hypoglycaemic episodes occurring after baseline (week 0) to end of treatment (week 16) in each treatment group. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. Symptoms only if subject was able to treat her/himself and with either no plasma glucose or blood glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L or 56 mg/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":219},"commonTop":["Hyperlipidaemia","Diarrhoea","Upper respiratory tract infection","Nasopharyngitis","Dyslipidaemia"]}}}